# A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

> **NCT04288687** · PHASE2 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 11 (actual)

## Conditions studied

- Prostate Adenocarcinoma

## Interventions

- **DRUG:** Niraparib Pill

## Key facts

- **NCT ID:** NCT04288687
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-19
- **Primary completion:** 2024-02-20
- **Final completion:** 2024-02-20
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04288687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04288687, "A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04288687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*